수면 연구가 새로운 수면무호흡증 약물로 이어지다

The development of AD109 marks a paradigm shift in treating Obstructive Sleep Apnea by replacing cumbersome mechanical CPAP devices with a simple oral pill, significantly improving patient compliance. This breakthrough, rooted in decades of neurological research, offers a scalable solution to prevent long-term complications like cardiovascular disease and cognitive impairment for millions of patients worldwide.